Abstract 1838
Background
Axitinib (AX) is an orally administered selective inhibitor of vascular endothelial growth factor (VEGF) receptor (R)-1/2/3. We previously reported that AX preliminarily showed promising activity against gemcitabine (GEM)-refractory biliary tract cancer (BTC), and we conducted this trial to confirm the efficacy and safety.
Methods
This single-arm phase II trial registered patients (pts) with advanced BTC refractory to GEM-based regimens. They were treated with an initial AX dose of 5 mg twice daily. The primary endpoint was progression-free survival (PFS). The secondary endpoints were overall response rate (ORR), overall survival (OS), and safety. Plasma biomarkers were measured at baseline and 1 month after treatment.
Results
Between July 2016 and August 2017, a total of 19 pts were enrolled from 3 centers; median age was 67 (range: 44–80) years, 10 (53%) were men. The ECOG performance status was 0 for 10 pts (53%) and 1 for 9 pts (47%). Nine pts (47%) had recurrent disease after surgery, 15 (79%) received GEM + cisplatin in first-line chemotherapy, and 13 (68%) received 2 or more chemotherapy regimens before enrollment. The primary sites were gallbladder, extrahepatic bile duct, and intrahepatic bile duct in 9 (47%), 6 (32%), and 4 (21%) pts, respectively. The median PFS was 2.8 months (95% confidence interval [CI]: 2.1–4.1), the ORR was 5.3% (95% CI: 0.0–15.3), and the median OS was 5.8 months (95% CI: 3.3–9.7). Treatment-related adverse events in this study were similar to those previously reported for renal cell carcinoma or thyroid cancer; however, ascites occurred in two pts possibly due to AX. Plasma biomarkers at both time points were evaluated in 16 pts. AX was associated with significant increases in VEGF-A and decreases in sVEGFR-1/2/3. Of the baseline biomarkers, high sVEGFR-2 and sVEGFR-3 were significantly associated with longer PFS and OS, respectively. High sVEGFR-3 and low VEGF-D tended to increase PFS, and high sVEGFR-2 and low VEGF-D tended to increase OS.
Conclusions
AX exhibited modest activity against GEM-refractory BTC. This trial suggested that ascites should be monitored as an adverse event. Baseline sVEGFR-2 and sVEGFR-3 may be useful biomarkers for AX.
Clinical trial identification
UMIN000023014.
Editorial acknowledgement
Legal entity responsible for the study
Kyorin University Faculty of Medicine.
Funding
Japan Agency for Medical Research and Development.
Disclosure
N. Okano: Honoraria (self): Taiho Pharmaceutical; Honoraria (self): Merck Serono; Honoraria (self): Eisai; Honoraria (self): Ono Pharmaceutical; Honoraria (self): Yakult Honsha; Honoraria (self): Takeda; Honoraria (self): J-Pharma; Honoraria (self): Kyowa Hakko Kirin. M. Ueno: Honoraria (self), Research grant / Funding (institution): Taiho Pharmaceutical; Honoraria (self), Research grant / Funding (institution): Yakult Honsha; Honoraria (self), Research grant / Funding (institution): AstraZeneca; Honoraria (self): Novartis; Honoraria (self): Lilly; Honoraria (self): Teijin Pharma; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Shire; Honoraria (self), Research grant / Funding (institution): Ono Pharmaceutical; Honoraria (self), Research grant / Funding (institution): Merck Serono; Research grant / Funding (institution): Daiichi Sankyo; Research grant / Funding (institution): Eisai; Research grant / Funding (institution): MSD; Research grant / Funding (institution): NanoCarrier; Research grant / Funding (institution): Dainippon Sumitomo Pharma; Research grant / Funding (institution): Incyte; Research grant / Funding (institution): ASLAN Pharmaceuticals. C. Morizane: Honoraria (self), Research grant / Funding (institution): Pfizer; Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Yakult Honsha; Honoraria (self): Lilly; Honoraria (self), Research grant / Funding (institution): Nobelpharma; Honoraria (self): Fujifilm; Honoraria (self): Teijin Pharma; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Taiho Pharmaceutical; Honoraria (self), Research grant / Funding (institution): Eisai; Advisory / Consultancy: AbbVie; Research grant / Funding (institution): Ono Pharmaceutical; Research grant / Funding (institution): J-Pharma. T. Yamanaka: Honoraria (self): Pfizer. H. Ojima: Research grant / Funding (institution): Pfizer Inc; Research grant / Funding (institution): Eli Lilly and Company; Research grant / Funding (institution): Merck Serono; Research grant / Funding (institution): Taiho Pharmaceutical. M. Ozaka: Honoraria (self): Taiho Pharmaceutical; Honoraria (self): Pfizer; Honoraria (self): Novartis; Honoraria (self): Bayer; Honoraria (self): Yakult Honsha; Honoraria (self): Eisai; Honoraria (self): EA Pharma. S. Kobayashi: Honoraria (self), Research grant / Funding (institution): Taiho Pharmaceutical; Honoraria (self), Research grant / Funding (institution): Kyowa Hakko Kirin; Honoraria (self), Research grant / Funding (institution): Daiichi Sankyo Pharmaceutical; Honoraria (self), Research grant / Funding (institution): Bayer; Honoraria (self), Research grant / Funding (institution): Eisai; Honoraria (self): Boston Scientific; Research grant / Funding (institution): Eli Lilly; Research grant / Funding (institution): Dainippon Sumitomo Pharmaceutical; Research grant / Funding (institution): Chugai Pharma; Research grant / Funding (institution): Yakult Honsha; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Takara Bio; Research grant / Funding (institution): Merck Serono; Research grant / Funding (institution): Ono Pharmaceutical; Research grant / Funding (institution): MSD; Research grant / Funding (institution): Boeringer Ingelheim; Research grant / Funding (institution): Beigene; Research grant / Funding (institution): Takeda Pharmaceutical. Y. Nakai: Honoraria (self), Research grant / Funding (self): Taiho Pharmaceutical; Honoraria (self): Daiichi Sankyo; Honoraria (self): AstraZeneca; Research grant / Funding (self): Eisai; Research grant / Funding (self): Yakult Honsha; Research grant / Funding (self): J-Pharma. M. Ikeda: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Novartis Pharma; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Bayer Yakuhin; Research grant / Funding (institution): Bristol-Myers Squibb; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Eisai; Honoraria (self): Taiho Pharmaceutical; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Eli Lilly Japan; Research grant / Funding (institution): Yakult; Advisory / Consultancy: Otsuka Pharmaceutical; Advisory / Consultancy: Daiichi-Sankyo; Honoraria (self): Sumitomo Dainippon Pharma; Honoraria (self), Advisory / Consultancy: Teijin Pharma; Honoraria (self): EA Pharma; Honoraria (self): Kaken Pharmaceutical; Advisory / Consultancy: Shire; Honoraria (self): MSD; Advisory / Consultancy, Research grant / Funding (institution): ASLAN Pharmaceuticals; Advisory / Consultancy, Research grant / Funding (institution): Chugai Pharmaceutical; Advisory / Consultancy, Research grant / Funding (institution): Ono Pharmaceutical; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Merck Serono; Research grant / Funding (institution): Nano Carrier; Honoraria (self): Gilead; Advisory / Consultancy: Astellas Pharma; Research grant / Funding (institution): Takeda Pharmaceutical; Research grant / Funding (institution): J-Pharma; Advisory / Consultancy: Micron. S. Maeno: Honoraria (self): Pfizer. F. Nagashima: Speaker Bureau / Expert testimony, Research grant / Funding (institution): Taiho; Speaker Bureau / Expert testimony, Research grant / Funding (institution): Ono; Speaker Bureau / Expert testimony, Research grant / Funding (institution): Merck Serono; Speaker Bureau / Expert testimony, Research grant / Funding (institution): Takeda; Speaker Bureau / Expert testimony, Research grant / Funding (institution): Chugai Pharma; Speaker Bureau / Expert testimony, Research grant / Funding (institution): Yakult Honsha; Speaker Bureau / Expert testimony, Research grant / Funding (institution): Sumitomo Dainippon; Speaker Bureau / Expert testimony, Research grant / Funding (institution): Kyowa Hakko Kirin; Speaker Bureau / Expert testimony: Mitsubishi Tanabe Pharma; Speaker Bureau / Expert testimony: Nestle health science; Speaker Bureau / Expert testimony, Research grant / Funding (institution): Janssen; Research grant / Funding (institution): Oncotherapy; Research grant / Funding (institution): Zeria Pharmaceutical; Research grant / Funding (institution): Lilly Japan; Research grant / Funding (institution): Daiichi Sankyo; Research grant / Funding (institution): Shionogi; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): J-Pharma; Research grant / Funding (institution): Bristol-Myers Squibb; Research grant / Funding (institution): Mochida Pharmaceutical Co. Ltd.; Research grant / Funding (institution): Astellas Pharma; Research grant / Funding (institution): Bayer; Research grant / Funding (institution): MSD; Research grant / Funding (institution): Eisai; Research grant / Funding (institution): Nano Carrier; Research grant / Funding (institution): Shire. T. Okusaka: Honoraria (self), Research grant / Funding (self), Research grant / Funding (institution): Novartis Pharma; Honoraria (self), Research grant / Funding (self), Research grant / Funding (institution): Ono Pharmaceutical; Honoraria (self), Research grant / Funding (self), Research grant / Funding (institution): Eisai; Honoraria (self), Research grant / Funding (self), Research grant / Funding (institution): Eli Lilly Japan; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Taiho Pharmaceutical; Honoraria (self): Yakult Honsha; Honoraria (self): Teijin Pharma; Honoraria (self): Shire; Honoraria (self): AbbVie; Honoraria (self), Advisory / Consultancy: Daiichi Sankyo; Honoraria (self): Takeda Pharmaceutical; Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Dainippon Sumitomo Pharma; Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution): Bristol-Myers; Research grant / Funding (self), Research grant / Funding (institution): Pfizer Japan; Research grant / Funding (self): Kyowa Hakko Kirin; Research grant / Funding (self), Research grant / Funding (institution): AstraZeneca; Research grant / Funding (self), Research grant / Funding (institution): Chugai Pharmaceutical; Research grant / Funding (self), Research grant / Funding (institution): Nano Carrier; Research grant / Funding (self), Research grant / Funding (institution): Baxter. J. Furuse: Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Eisai; Honoraria (self), Research grant / Funding (self): Bayer Yakuhin; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Taiho Pharmaceutical; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Ono Pharmaceutical; Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self), Research grant / Funding (self): Yakult Honsha; Honoraria (self): Teijin Pharma; Honoraria (self): Shionogi; Honoraria (self): EA Pharma; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Eli Lilly Japan; Honoraria (self), Research grant / Funding (self): Takeda; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Chugai Pharma; Honoraria (self), Research grant / Funding (self): Mochida Pharmaceutical; Honoraria (self): Nihon Servier; Honoraria (self), Research grant / Funding (self): Sanofi; Honoraria (self), Advisory / Consultancy: Fujifilm; Honoraria (self): Nobel Pharma; Honoraria (self), Research grant / Funding (self): Pfizer; Honoraria (self): Sawai Pharmaceutical; Honoraria (self), Research grant / Funding (self): Daiichi Sankyo; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Sumitomo Dainippon; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Astellas Pharma; Honoraria (self), Advisory / Consultancy: Merck Serono; Honoraria (self): Nippon Kayaku; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): MSD; Honoraria (self), Advisory / Consultancy: Shire; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): AstraZeneca; Honoraria (self), Advisory / Consultancy: J-Pharma; Honoraria (self), Advisory / Consultancy: AbbVie; Honoraria (self), Research grant / Funding (self): Kyowa Hakko Kirin; Advisory / Consultancy: Takara Bio; Advisory / Consultancy: Otsuka; Research grant / Funding (self): Nano Carrier. All other authors have declared no conflicts of interest.
Resources from the same session
5134 - Early prediction of the platinum-resistant relapse risk using the CA125 modeled kinetic parameter KELIM: a pooled analysis of AGO-OVAR 7 & 9; ICON 7 (AGO/GINECO/ MRC CTU/GCIG trials).
Presenter: OLIVIER COLOMBAN
Session: Poster Display session 2
Resources:
Abstract
4410 - Mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with carboplatin and bevacizumab: Initial results from a Phase 1b study in patients (pts) with ovarian cancer
Presenter: David Omalley
Session: Poster Display session 2
Resources:
Abstract
5077 - Response to Pegylated Liposomal Doxorubicin (PLD) and Weekly Paclitaxel (wpac) in Platinum Resistant (PR) Ovarian Cancer (OC) by BRCA mutation status
Presenter: Louise Bremer
Session: Poster Display session 2
Resources:
Abstract
3483 - Impact of prior pegylated liposomal doxorubicin (PLD) treatment in recurrent ovarian cancer (ROC): Sub-group analysis from a randomized, open-label study comparing trabectedin (T) and PLD versus PLD alone in ROC (ET743-OVC-3006)
Presenter: Bradley Monk
Session: Poster Display session 2
Resources:
Abstract
5423 - OCTAVE - A phase I study of enadenotucirev, an oncolytic group B adenovirus, in combination with weekly paclitaxel in platinum-resistant epithelial ovarian cancer
Presenter: Iain McNeish
Session: Poster Display session 2
Resources:
Abstract
1385 - Phase I study of low dose whole abdominal radiation therapy (LDWART) in combination with weekly paclitaxel (wP) for platinum resistant ovarian cancer (PROC)
Presenter: Natalie Ngoi
Session: Poster Display session 2
Resources:
Abstract
2090 - Phase 1b/2a study assessing the safety and efficacy of adding AL3818 (Anlotinib) to standard platinum-based chemotherapy in subjects with recurrent or metastatic endometrial, ovarian or cervical carcinoma
Presenter: David Miller
Session: Poster Display session 2
Resources:
Abstract
1960 - Phase I Study of Intraperitoneal TRX-E-002-1 in Subjects with Persistent or Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer: Three-month Follow-up Results of the Dose Escalation Phase
Presenter: Jermaine Coward
Session: Poster Display session 2
Resources:
Abstract
4288 - Hybrid capture-based genomic profiling of circulating tumor DNA (ctDNA) from patients with ovarian cancer
Presenter: Mi Yang
Session: Poster Display session 2
Resources:
Abstract
3433 - Tumor Microvessel Density for predicting Nintedanib activity: data from the randomized CHIVA trial (a GINECO study)
Presenter: Maud Villemin
Session: Poster Display session 2
Resources:
Abstract